Bi­cy­cle Ther­a­peu­tics takes Roche's Genen­tech on an up to $2B im­muno-on­col­o­gy ride

Bi­cy­cle Ther­a­peu­tics — which is de­vel­op­ing a new class of chem­i­cal­ly syn­the­sized drugs de­signed to be phar­ma­co­log­i­cal­ly as ac­tive as bi­o­log­ics, yet man­u­fac­tured as small mol­e­cules —  has scored an­oth­er big part­ner: Roche’s Genen­tech.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.